Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to evaluate the cost-effectiveness, from the Hong Kong health-care provider's perspective, of CYP2C19*2 genotype-guided selection of antiplatelet therapy compared with the universal use of clopidogrel or ticagrelor among ACS patients who undergo percutaneous coronary intervention (PCI).
|
28117433 |
2018 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel.
|
22974536 |
2012 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we evaluated the clinical outcomes of DAPT guided by CYP2C19 polymorphisms after implantation of second-generation drug-eluting stents (DESs) for ACS management.
|
29279531 |
2018 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
|
28734158 |
2017 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using both CYP2C19 GOF and LOF alleles to select antiplatelet therapy appears to be the preferred antiplatelet strategy over universal clopidogrel and universal alternative P2Y<sub>12</sub> inhibitor therapy for ACS patients with PCI.
|
27924429 |
2017 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19*2 allele and HPR by ADP are both independently associated with an increased risk of MACE in the first 6 months after ACS.
|
22390861 |
2012 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 and PON1 Q192R variants influence ADP-induced platelet inhibition by thrombelastography (TEG) in ACS patients with clopidogrel.
|
31772608 |
2019 |
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>CYP2C19*2</i> and <i>CYP2C19*17</i> carrier status correlates with PR in ACS patients treated with clopidogrel and thus might be useful for pre-selecting patients who will and who may not be suitable for PGDE of anti-platelet treatment.
|
30103241 |
2018 |
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants.
|
29936693 |
2018 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Presence of specific CYP2C19 allele significantly influences clopidogrel metabolism and associated outcomes in patients with ACS.
|
31498157 |
2019 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity (A/A) for CYP2C19*2 mutant is an independent determinant of prognosis in patients with ACS.
|
21778720 |
2011 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventy-six patients (median age 63, range 37-91 years) with an ACS who underwent PCI were screened for <i>CYP2C19</i> and <i>ABCB1</i> gene polymorphisms with real-time polymerase chain reaction: <i>CYP2C19*2</i>, <i>CYP2C19*17</i>, and <i>ABCB1 3435</i>.
|
29075133 |
2017 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
|
26521100 |
2016 |
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to investigate the frequency of <i>CYP2C19*2, *3</i> allelic variants, associated with poor response to clopidogrel, and <i>CYP2C19*17</i>, associated with excessive response to clopidogrel, in patients with acute coronary syndrome (ACS) from Siberia and Moscow regions of Russia.
|
28442925 |
2017 |
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although limited prospective trial data are available to support the utility of routine CYP2C19 testing, the increased risks for reduced clopidogrel efficacy among ACS/PCI patients that carry CYP2C19 loss-of-function alleles should be considered when genotype results are available.
|
26173871 |
2015 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study further explored the relationship between CYP2C19 polymorphisms and clopidogrel resistance in ACS patients.
|
27323099 |
2016 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study sought to assess the effect of CYP2C19 genotype on ischemic outcomes in patients with ACS initially managed medically without revascularization who were randomized to either clopidogrel or prasugrel.
|
26916483 |
2016 |
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 metabolizer status and GRACE score are readily available predictive approaches for MACEs, and their combination derives a more accurate long-term MACE prediction in clopidogrel-treated patients with ACS undergoing PCI.
|
30193195 |
2018 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seven studies including cost-effectiveness and risk-benefit analyses of CYP2C19 genotype-guided antiplatelet therapy in ACS patients were reviewed.
|
25660101 |
2015 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS).
|
27977637 |
2016 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study aims to examine the frequency of CYP2C19 variants and understand the factors associated with on-treatment platelet reactivity in a New Zealand ACS population.
|
25583161 |
2015 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the present study was designed to investigate the impact of CYP2C19 loss-of-function point-of-care (POC) genotyping in patients presenting with acute coronary syndromes (ACS) and treated with dual antiplatelet therapy in the emergency setting.
|
24856643 |
2014 |
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This research evaluated the frequency of variant alleles in the genes coding for CYP3A4, CYP3A5, CYP2C9, and CYP2C19 enzymes in patients on clopidogrel therapy and experiencing repeat acute coronary syndrome (ACS) compared to a control group with a matching ethnic composition.
|
19337788 |
2009 |
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six strategies for selection of P2Y<sub>12</sub> inhibitors in ACS were compared from the US healthcare system perspective: (1) clopidogrel for all (universal clopidogrel); (2) ticagrelor guided by platelet reactivity assay (PRA; clopidogrel + phenotype); (3) ticagrelor use only in CYP2C19 poor metabolizers (genotype + conservative ticagrelor); (4) ticagrelor use in both CYP2C19 intermediate and poor metabolizers (genotype + liberal ticagrelor); (5) ticagrelor use only in patients with CYP2C19 polymorphisms and clopidogrel nonresponse by PRA (genotype + phenotype); and (6) ticagrelor for all (universal ticagrelor).
|
31367811 |
2019 |
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The null allele in the CYP2C19 (rs4244285) [odds ratio (OR)=5.317, 95% confidence interval (CI) 1.542-26.428, P=0.001] and CYP2C19 (rs4986893) (OR=4.295, 95%CI 1.312-17.517, P=0.013) is one of the causes of CR in patients with ACS in China.
|
31543510 |
2019 |